Sangamo Therapeutics Stock Price and Value Analysis

Sangamo Therapeutics (NasdaqGS:SGMO) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Sangamo Therapeutics to reach your target.

Target type

SGMO Free Cash Flow Trend

Free Cash Flow trendline for SGMO
Free Cash Flow trendline for Sangamo Therapeutics

Hmm, we can't give any reliable projection for Sangamo Therapeutics's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

AdvantagesDisadvantagesNeutral
  • This company is solid.
  • This company is not making money.
  • This company has wild ups and downs.
  • This stock looks overpriced.
  • This company pays no dividend.

Inside the SGMO Numbers

SGMO Price
(Sangamo Therapeutics stock price per share)
$0.00
[?] PE Ratio versus Sector 100% lower than other Healthcare stocks
[?] PE Ratio versus Industry 100% lower than other Biotechnology stocks
[?] Cash Yield -109.92%
[?] Free Cash Flow Jitter 142%

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Net income was negative in all 17 fiscal years from 2009 to 2025, so no ratio of operating cash flow to net income is shown. Operating cash flow totaled -$962 million over those years, against net income of -$1,455 million.

In 2025, net income was -$123 million and operating cash flow was -$97.2 million, so no ratio is shown for that year.

In 2020, capital expenditures were $14.7 million, 8.7% of operating cash flow of $170 million, which leaves an estimated $155 million after capex. Across the 3 years with reported capex, it averaged 28.3% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2009 -18.6 -6.1 0.3 n/a
2010 -24.9 -23.9 0.7 n/a
2011 -35.8 -25.9 0.6 n/a
2012 -22.3 -8.1 0.7 n/a
2013 -26.6 -19.5 0.4 n/a
2014 -26.4 -5.7 0.6 n/a
2015 -40.7 -33.7 2.4 n/a
2016 -71.7 -65.9 0.7 n/a
2017 -54.6 11.2 3.8 n/a
2018 -68.3 36.5 43.1 n/a
2019 -95.2 -144 20.7 n/a
2020 -121 170 14.7 n/a
2021 -178 -233 23.3 n/a
2022 -192 -224 20.2 n/a
2023 -258 -225 21.2 n/a
2024 -97.9 -67.1 0.3 n/a
2025 -123 -97.2 0.1 n/a

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $22.2 million in 2009 and $39.6 million in 2025, a compound annual growth rate of 3.7% over 16 years.

Revenue fell 31.6% from 2024 to 2025.

Our estimated free cash flow was -$110 million in 2025, a negative margin of 278.6% of revenue, meaning the estimate was below zero. In 2009 the estimated margin was negative 28.9%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2009 22.2 -6.4 -28.9%
2010 20.8 -24.4 -117.4%
2011 10.3 -26.4 -255.9%
2012 21.7 -8.6 -39.9%
2013 24.1 -20 -83.0%
2014 45.9 -6.3 -13.7%
2015 39.5 -34.7 -87.7%
2016 19.4 -66.9 -344.9%
2017 36.6 9.6 26.2%
2018 84.5 26.4 31.3%
2019 102 -159 -154.8%
2020 118 153 129.7%
2021 111 -254 -229.8%
2022 111 -248 -222.8%
2023 176 -245 -138.9%
2024 57.8 -83.1 -143.7%
2025 39.6 -110 -278.6%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $20.9 million against total liabilities of $74 million, or 28.3% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 123.9% of total assets in 2025, compared with 11.3% in 2010, an increase of 112.6 percentage points.

Stockholders equity was negative in 2025, at -$14.3 million, which means the company's liabilities and other claims on its assets exceeded the assets themselves. Companies that return cash through large buybacks can show negative equity for that reason alone, but it also leaves no book value cushion for shareholders.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2010 63 10.8 7.1 55.9
2011 87.3 16.8 7.2 80.1
2012 82.5 21.7 17.6 64.9
2013 141 10.2 19.1 122
2014 243 6 36.6 207
2015 217 69.5 24.8 192
2016 158 22.1 21.7 136
2017 287 49.8 98.8 188
2018 590 140 223 367
2019 638 80.4 205 433
2020 939 131 441 497
2021 722 179 347 375
2022 563 100 268 295
2023 165 45.2 82.4 82.9
2024 102 41.9 78.9 22.8
2025 59.7 20.9 74 -14.3

Price Versus Our Estimated Value

Of the 17 fiscal years we can see for Sangamo Therapeutics under its current filer, 3 show positive free cash flow.

We do not estimate a fair value for Sangamo Therapeutics while its free cash flow growth is not positive, so there is no value comparison here.

Year-to-year variability in free cash flow is volatile, measured at 142%.

Dividends are not in our data for Sangamo Therapeutics.

Our value investing guide explains how to test these numbers against the filings themselves.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 100% below the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 100% below the average for stocks in the Biotechnology industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Biotechnology industry, the ones closest in market capitalization to Sangamo Therapeutics, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Sangamo Therapeutics (SGMO) - - - - -
Amgen (AMGN) 235,643 25.3 2.3% 4.5% 11% below
Biogen (BIIB) 36,894 108.0 - 10.0% 69% below
Neurocrine Biosciences (NBIX) 15,240 22.3 - - 469% above
Repligen Corporation (RGEN) 10,471 - - - 397% above
Bio-Techne Corporation (TECH) 11,416 66.7 0.3% 1.4% 90% above

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1001233.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow was negative in 14 of the 17 years we have.
  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • We have no value estimate for this stock, so no price comparison is made.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: SGMO annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in SGMO

Does Sangamo Therapeutics have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: SGMO

This example shows how we apply the Trendshare checklist to SGMO: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 0.00
    • Market cap: —
    • EPS: —
  2. Step 2 — Valuation checks

    • P/E: —
    • FCF yield: —
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.